.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, people along with metastatic stomach growths who got biomarker-matched therapies based upon circulating tumor DNA profiling presented a greater professional advantage than those getting unrivaled therapy.